Analyze how Gilead's competitive moat in HIV…

Gilead’s HIV franchise remains the primary revenue engine through 2029, anchored by Biktarvy’s durable dominance and lenacapavir’s long-acting PrEP launch, even as Merck introduces a credible but limited 2-drug alternative. Biktarvy generated $14.3 billion in 2025 sales (up 7% YoY) within a $20.8 billion HIV portfolio, supported by >52% U.S. market share and ongoing gains in naïve and switch patients. Lenacapavir (branded Yeztugo/Yeytuo for PrEP) launched in the U.S. in mid-2025 with $150 million in initial sales and a $800 million target for 2026, leveraging twice-yearly subcutaneous dosing that addresses adherence barriers far better than daily orals. A Gilead-Merck collaboration is advancing a weekly oral islatravir + lenacapavir regimen into Phase 3, positioning the pair for a potential first-in-class long-acting oral option.[1][2]

• Merck’s Idvynso (doravirine/islatravir) received FDA approval in April 2026 as a once-daily 2-drug regimen non-inferior to Biktarvy in Phase 3 for virologically suppressed patients; analysts view its near-term impact on Gilead as limited at most, given Biktarvy’s entrenched position and broader label.[3][4]
• Biktarvy patent protection extends into the mid-to-late 2030s (references to 2033–2036 exclusivity), delaying meaningful generic erosion well beyond 2029.
• Lenacapavir PrEP manufacturing capacity targets up to 10 million doses by 2026 (supporting ~2.5 million users), with global access initiatives and EU positive CHMP opinion under accelerated review.

Implication for competitors: New entrants must overcome not just efficacy but also real-world adherence data, payer preference for established regimens, and Gilead’s integrated treatment-prevention ecosystem. Long-acting differentiation is now table stakes; daily orals face structural disadvantages.

Oncology faces a bifurcated outlook—Trodelvy (TROP-2 ADC) has expansion runway in a high-growth ADC market, while Yescarta (CAR-T) contends with share erosion and logistical headwinds despite overall market expansion. Yescarta sales declined ~5% in recent quarters (part of a 7% drop in cell therapy revenue to ~$1.84 billion in 2025), attributed to competitive pressure from other approved CAR-Ts (e.g., Breyanzi) and U.S. demand softness amid manufacturing and access complexities. The broader CAR-T market is projected to grow at ~16.5% CAGR through the early 2030s, but early leaders like Yescarta are ceding ground. Trodelvy benefits from the ADC wave (overall market CAGR estimates ~28% in some forecasts), though specific long-term consensus numbers remain sparse amid competition from agents like Enhertu.[5][6]

• Gilead’s recent acquisitions (e.g., Arcellx) target next-generation CAR-T and other modalities to refresh the portfolio, with 2026 potential launches noted in company commentary.
• Biosimilar or generic risk for these complex biologics/cell therapies is low in the near term due to manufacturing barriers and regulatory hurdles for ADCs/CAR-Ts.

Implication: Oncology contribution to total revenue growth will likely be incremental rather than transformative through 2029 unless new approvals accelerate. Success hinges on pipeline execution and differentiation in crowded ADC/CAR-T fields; pure-play competitors may struggle against integrated players with established commercial infrastructure.

Inflammation remains a minor and uncertain contributor, with filgotinib largely sidelined by prior regulatory setbacks and IL-2 programs still early-stage. Filgotinib (JAK inhibitor, partnered with Galapagos) faced FDA rejection in rheumatoid arthritis in 2020 over risk-benefit concerns and has seen limited subsequent advancement in major indications. No prominent recent sales or pipeline updates position it as a material revenue driver. IL-2 assets appear preclinical or early clinical, with no disclosed late-stage data or consensus projections.

• No meaningful biosimilar exposure or competitive moat details emerge for these assets in public filings or reports.

Implication: This area offers limited defensive or offensive value through 2029. Any revival would require fresh positive data and approvals not currently visible in sell-side narratives.

Sell-side consensus frames a stable-to-modestly growing revenue trajectory centered on the HIV base business, with 2026 guidance around $29.6–$30.4 billion (midpoint ~$30 billion, ~5–6% growth) after 2025 actuals of ~$29.4 billion total revenue. Analyst models for 2026 cluster near $30.2 billion, reflecting HIV momentum (6% expected growth, or 8% ex-policy headwinds) offset by Veklury decline and cell therapy softness. Longer-term (2027–2029) public consensus is less granular but implies continued low-to-mid single-digit growth absent major LOE events, with HIV comprising the majority of the base.[7][8]

Key swing factors (independent of AI or speculative pipeline bets):
- Lenacapavir PrEP uptake speed and global access (U.S. penetration, EU launch, LMIC procurement).
- Merck collaboration outcomes and any share shifts from Idvynso or future regimens.
- Oncology new product approvals and competitive intensity in ADCs/CAR-T.
- Policy/pricing pressures (IRA Medicare negotiations, payer mix).
- Patent defense success and any early generic challenges.

Bull case narrative (~$38–42 billion revenue by 2029, 6–8%+ CAGR): Lenacapavir PrEP exceeds targets and captures significant share of a growing prevention market (potentially multi-billion globally), Biktarvy maintains or grows share through 2029 on superior real-world data, and Trodelvy plus new oncology launches add meaningful incremental revenue. HIV portfolio reaches ~$25–28 billion; overall growth accelerates as long-acting options expand the addressable market without major competitive losses.

Base case narrative (~$34–37 billion by 2029, 3–5% CAGR): HIV grows steadily at 4–6% annually from Biktarvy stability and lenacapavir ramp to $1–2+ billion, offset by modest cell therapy declines and pricing headwinds. Oncology contributes low-single-digit growth via pipeline fills. Total revenue tracks consensus-like modest expansion, with HIV still ~70%+ of the mix and no major LOE cliff before 2030.

Bear case narrative (~$28–32 billion by 2029, flat to slight decline): Merck’s regimens and other competitors erode Biktarvy share faster than expected; lenacapavir uptake disappoints due to access, reimbursement, or safety signals; CAR-T revenue continues contracting amid intensified competition and reimbursement challenges; oncology pipeline delays materialize. HIV growth slows to low-single digits or flattens, and total revenue plateaus or dips modestly as Veklury fades without sufficient offsets.

These scenarios rely on publicly reported 2025 actuals, 2026 guidance, and near-term analyst commentary; longer-horizon sell-side models are less detailed and would benefit from updated reports closer to 2027. Patent longevity and long-acting innovation provide the core moat resilience, but execution on lenacapavir commercialization and oncology refresh will determine whether growth remains HIV-dependent or diversifies.

---

Recent Findings Supplement (May 2026)

Gilead’s HIV franchise (Biktarvy + lenacapavir-based assets) remains the primary near-term growth engine through at least 2029, with Q1 2026 sales showing continued momentum despite emerging Merck competition. Biktarvy posted $3.4 billion in Q1 2026 (+7% YoY), driving overall HIV product sales to approximately $5.0 billion (+10% YoY), while the U.S. PrEP business surged 87% thanks to Descovy and the early ramp of Yeztugo (twice-yearly injectable lenacapavir PrEP, approved in 2025). The company raised 2026 base business revenue guidance to $29.4–29.8 billion (implying 5–6% growth), citing strong demand for Biktarvy, Descovy, and Yeztugo.[1][2]

A key new catalyst is the FDA’s priority review acceptance (April 2026) of the once-daily oral bictegravir + lenacapavir (BIC/LEN) single-tablet regimen for virologically suppressed patients, with a PDUFA date of August 27, 2026, supported by positive Phase 3 ARTISTRY-1/2 data presented at CROI 2026. Biktarvy maintains exclusivity into the mid-2030s, providing a durable base.[3]

• Merck threat materialized but appears contained: FDA approved Merck’s doravirine/islatravir (DOR/ISL; Idvynso) on April 21, 2026, as a once-daily two-drug regimen for switch in suppressed adults with no prior failure or DOR resistance. Phase 3 data showed non-inferiority to Biktarvy in both treatment-naïve and switch settings; it is the first non-INSTI, tenofovir-free complete regimen. Analysts view it as a differentiated alternative rather than a direct displacer of Biktarvy’s market leadership.[4][5]
• Collaborative offset: Gilead and Merck continue Phase 3 development of islatravir + lenacapavir as a potential once-weekly oral regimen.
• Implication for competitors: New entrants must demonstrate clear advantages in convenience, tolerability, or resistance profile to meaningfully erode Gilead’s >50% U.S. treatment share; long-acting options like Yeztugo create switching friction.

Trodelvy’s growth trajectory is accelerating with label-expansion catalysts expected in 2H 2026, while Kite’s CAR-T platform is being upgraded via M&A to counter solid-tumor and next-gen cell therapy competition. Trodelvy sales reached $402 million in Q1 2026 (+37% YoY), supported by NCCN Category 1 recommendations in metastatic triple-negative breast cancer (mTNBC). FDA and EC decisions for first-line mTNBC are anticipated in 2H 2026, alongside Phase 3 updates for EVOKE-03 (Trodelvy + pembrolizumab in PD-L1-high metastatic NSCLC) and ASCENT-GYN-01 (2L metastatic endometrial cancer). CHMP issued a positive opinion for 1L mTNBC in PD-(L)1 inhibitor-ineligible patients.[1][6]

Gilead completed the Arcellx acquisition (announced earlier in 2026, ~$7.8 billion equity value plus CVR) to bolster its Kite CAR-T franchise with anito-cel (BCMA-targeted for relapsed/refractory multiple myeloma); the BLA was accepted with a December 23, 2026 PDUFA date. The deal also adds a D-Domain BCMA binder platform potentially useful across oncology and inflammation. Additional deals (Tubulis, Ouro) target ADC and T-cell engager technologies.[3]

• ADC competition intensifying: AstraZeneca/Daiichi Sankyo’s Datroway (TROP2 ADC) outperformed Trodelvy in certain first-line TNBC head-to-head contexts; the key Avanzar readout (Datroway + Imfinzi in 1L NSCLC) is now expected in 2H 2026.
• CAR-T landscape: BMS and others continue expanding footprints; next-gen approaches (e.g., rapid manufacturing, in vivo CAR-T) represent longer-term risks.
• Implication: Trodelvy could approach or exceed $1–2 billion annual sales post-1L approvals if data hold; Kite needs Arcellx and pipeline execution to maintain relevance beyond lymphoma.

Inflammation efforts remain early-stage and de-emphasized relative to HIV and oncology, with filgotinib showing limited recent commercial traction and IL-2 programs not prominently featured in 2026 updates. Filgotinib (Jyseleca) has faced prior regulatory and commercial headwinds in rheumatoid arthritis and other indications; recent commentary notes uneven execution in autoimmune/inflammatory diseases. Gilead is pivoting via M&A, including the Ouro Medicines acquisition (announced March 2026, $1.67 billion, split with Galapagos) for OM336, a first-in-class BCMA×CD3 T-cell engager in Phase 1/2 for autoimmune hemolytic anemia and immune thrombocytopenia (fast-track and orphan designations; registrational studies expected 2027).[7]

Livdelzi (seladelpar for primary biliary cholangitis) is contributing positively to revenue but is not a major moat driver. IL-2-related assets (e.g., potential early programs like GS-1427/α4β7) receive minimal visibility in recent earnings materials or pipeline highlights.

• Implication: This area offers optionality but is unlikely to materially impact revenue through 2029 without clinical success from newer platforms; competition from established JAK inhibitors and other modalities remains high.

Sell-side consensus and company guidance point to mid-single-digit revenue growth through 2029, anchored by HIV durability and oncology expansion, with 2026 base business revenue guided at $29.4–29.8 billion. Analyst models generally align with or slightly above company guidance for 2026 (~$29–30 billion total product sales), with continued ~5% compound annual growth projected into the low-to-mid $30 billions by 2028–2029, driven by HIV (Biktarvy + lenacapavir franchise) and rising contributions from Trodelvy and cell therapy. Large acquired IPR&D charges (~$11.5 billion expected in Q2 2026) will pressure 2026 GAAP EPS (company guidance implies a net loss), but non-GAAP/base business metrics remain constructive.[8][9]

Key swing factors include:
- Positive: Successful BIC/LEN and Trodelvy 1L launches; faster Yeztugo adoption; positive Arcellx integration and new indication data.
- Negative: Greater-than-expected Merck DOR/ISL share gains; Datroway or other ADC competition eroding Trodelvy momentum; regulatory delays or safety signals.
- Neutral/Base: HIV grows 5–7% annually through 2029; Trodelvy reaches blockbuster status; oncology (including cell therapy) contributes progressively larger share.

Overall narrative through 2029: Gilead’s moat is most durable in HIV due to Biktarvy’s entrenched position, long-acting innovations, and extended exclusivity, providing a stable cash flow base for oncology investments. Oncology offers the highest upside but faces credible ADC and CAR-T competition that M&A is actively addressing. Inflammation is a secondary priority with deal-driven optionality. Revenue is likely to track in the $30–37 billion range by 2029 under base assumptions, with swings of several billion dollars possible depending on launch execution and competitive dynamics. Biosimilar risk remains low until the mid-2030s for core assets.